🔗 Share this article

While the United States proceeds with historic revisions to its immunization schedules, a particular individual appears in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who rose to prominence by questioning Covid vaccinations during the global health crisis and has focused upon possible deaths following Covid immunization in her brief time at the FDA.

Planned Overhauls to Childhood Immunization Schedule

Health officials planned to reveal major revisions to the pediatric immunization program earlier this month, bringing the US with Denmark’s immunization schedule, it is understood – a substantial departure that would place the US out of step with much of the international standard with little proof for benefit. The planned update has been pushed back until the next year.

Rather than Vinay Prasad, Dr. Høeg is set to address the audience at the meeting. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the division this year.

Consolidating Power at the FDA

This interim role might represent a tighter collaboration between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad solidify control at the agency – and it points to a renewed priority upon rolling back long-standing vaccines at the FDA.

Høeg has repeatedly called for discontinuing certain pediatric vaccine recommendations in the US so as to align more in line with Denmark, a society with nationalized medicine and a number of inhabitants approximately the size of Wisconsin’s.

So far statements, she has kept her attention on immunizations – usually the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Concerns Over Expertise

The appointee has little discernible track record in pharmaceutical research, regulation or administrative roles, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“She appears not to have the necessary background” for overseeing the drug-regulation department, stated a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in leading a major agency. She has no expertise in industry regulation.”

Past commissioners of the center would “grasp laws and regulations and the underlying principles of pharmaceutical innovation”, noted a former acting FDA commissioner. “Objectively, she doesn’t have the sort of resume that former directors who led the center have had.”

This division has an vast workload at the agency, the former commissioner pointed out.

“Many people just pays attention on the new drug program, but the off-patent medication office clears numerous generic medications. There is also a biosimilars program, over-the-counter program and other areas, and each of these have to be supervised,” Dr. Woodcock noted. “The thing you neglect, that is the part that I always told people is going to bite you.”

There is also, a major administrative element to the position, which manages more than 5,000 staff members. “It’s a massive management job, if you execute it properly,” Woodcock added.

Agency Reaction and Disputed Policies

When asked about inquiries about Høeg’s fitness for the role and whether this appointment represents more teamwork among agency officials on immunizations, a representative said that the “questions stem from incorrect presumptions”.

“Her resume aligns with the responsibilities of her role,” the representative said, noting the time Dr. Høeg spent advising the agency head on “drug safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the commissioner’s recently launched fast-track approval initiative, a controversial one-day medication authorization process that allegedly concerned her former heads. “By what process are these therapies being selected for this fast-track system? Who takes the choices?” Howard asked. “There is a lot of secrecy going on at the FDA right now.”

Broadly speaking, he stated, “the FDA appears to be shifting towards laxer oversight of pharmaceuticals, with the exception of vaccines.”

Public History on Immunizations

With vaccines, Dr. Høeg has a more established, if troubling, track record, critics said. She released a study using unverified public submissions to assess the frequency of myocarditis following Covid immunization. She advised the state of Florida chief medical officer Joseph Ladapo, who was said to have modified findings to suggest Covid vaccines are riskier than they are.

Among her “policy goals” for the current federal leadership featured altering rules for novel immunizations and discontinuing “non-essential” vaccines, she said after the election on a audio program. At the agency, Dr. Høeg has reportedly proposed preventing teenage boys from getting COVID-19 vaccines.

“She is an complete ideologue who begins with her conclusions and tailors the evidence to accommodate the data in a highly misleading, fraudulent way,” Howard argued.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg joined fellow skeptics, {like|